What Does a Chemo Rash Look Like? Symptoms & Photos

Chemotherapy rash most often appears as clusters of small, pus-filled bumps and red papules that look strikingly similar to a breakout of acne, concentrated on the face, scalp, upper chest, and back. The exact appearance depends heavily on which drug is causing it, though, and “chemo rash” is really an umbrella term covering everything from that acne-like eruption to painful, peeling palms and soles, widespread flat red patches, and even blistering reactions. Because targeted therapies and immunotherapies have become standard parts of cancer treatment, skin reactions are now among the most frequently reported side effects, and recognizing what you’re seeing on your skin is the first step toward getting the right care for it.

The Acneiform Rash From EGFR Inhibitors

The single most recognizable chemo-related rash comes from a class of drugs called EGFR inhibitors, which include erlotinib, cetuximab, and panitumumab. This rash is so common that it shows up in roughly half to nearly all patients who take these drugs.¹ Visually, it presents as a papulopustular eruption: clusters of small red bumps (papules), many of which develop white or yellowish heads of pus (pustules). At a glance, it looks a lot like teenage acne or even a bacterial skin infection, which is one reason it gets misidentified so often.²

There are a few visual clues that separate it from ordinary acne. The bumps tend to be more uniform in size, there are usually no blackheads or whiteheads (the comedones typical of acne), and the surrounding skin is often visibly dry and inflamed rather than oily. The eruption can also appear on areas where acne rarely shows up in adults, such as the scalp and the back of the arms. In severe cases, the bumps merge into large, angry-looking patches with crusting, and the skin between them becomes noticeably red and flaky.

Where It Shows Up on the Body

The distribution of chemo rash follows a fairly predictable pattern depending on the drug type. EGFR inhibitor rashes concentrate in seborrheic areas, the zones of your skin richest in oil glands. That means the face gets hit first and hardest, particularly the forehead, nose, and cheeks. From there, the rash typically spreads to the scalp (where it can feel like a painful, bumpy sunburn hidden under your hair), the upper chest and upper back, and sometimes the shoulders. The trunk and legs are usually less affected, though in severe cases the rash can become more widespread.

Other drug classes produce skin reactions in completely different locations. Capecitabine, doxorubicin, and other traditional chemotherapy agents are more likely to cause generalized rashes that appear across the torso and limbs without the strong face-and-scalp concentration. Some reactions are highly localized; hand-foot syndrome, for instance, targets just the palms and soles.

How It Feels, Not Just How It Looks

Photos can capture the visual side of chemo rash, but patients consistently report that the sensation is just as disruptive. The most common skin-related side effects during chemotherapy include rash, dry skin, itching, nail changes, hair changes, and mouth sores.³ Itching ranges from mild annoyance to the kind that wakes you up at night. The skin often feels tight, dry, and sensitive to the touch, and some patients describe a burning or stinging quality in the most affected areas. The pustules themselves are usually tender rather than truly painful, but when the rash covers large areas of the face, everyday activities like washing, shaving, or even resting your face on a pillow become uncomfortable.

Dry skin (xerosis) is worth calling out separately because it often accompanies the rash and can persist long after the bumps improve. The skin may crack, especially on the fingertips, knuckles, and heels, and these cracks can sting and bleed. This widespread dryness is not just cosmetic; cracked skin is a route for secondary infections, which is a real concern in someone whose immune system is already suppressed by treatment.

Hand-Foot Syndrome Looks Very Different

One of the most common skin reactions that gets lumped under “chemo rash” doesn’t look like a rash at all. Hand-foot syndrome (also called palmar-plantar erythrodysesthesia) is a reaction to certain chemotherapy drugs, including capecitabine, pegylated liposomal doxorubicin, and fluoropyrimidines.⁴ It starts with redness and tingling on the palms of the hands and soles of the feet. Over days, the affected skin becomes swollen, tender, and may develop blisters. In advanced cases, the skin peels off in sheets, and the pain can make it difficult to walk or grip objects.

The visual difference is stark: hand-foot syndrome produces a deep, symmetric redness on the palms and soles that looks almost like a bad sunburn confined to just those areas, sometimes with visible blistering and desquamation (peeling). It doesn’t produce the pimple-like bumps of an acneiform rash, and it doesn’t appear on the face. If you’re seeing red, peeling palms and soles during chemo, you’re almost certainly dealing with hand-foot syndrome rather than a generalized drug rash.

Rashes From Immunotherapy

Immune checkpoint inhibitors like pembrolizumab and nivolumab have become a major part of cancer treatment, and they bring their own set of skin reactions that look different from classic chemo rash. The most common is a maculopapular rash, which appeared in about three-quarters of patients with skin reactions in one clinical study.⁵ Maculopapular means a mix of flat discolored spots (macules) and raised bumps (papules), often scattered across the trunk and limbs. It tends to look more like a drug allergy rash than acne: widespread, relatively flat, and pink-to-red rather than bumpy and pustular.

Immunotherapy can also trigger less common but more distinctive reactions, including a psoriasis-like pattern with scaly plaques, a lichenoid reaction with small flat-topped bumps and a purplish hue, and in rare cases, blistering conditions where the immune system attacks the skin more aggressively. These varied presentations mean that a skin reaction during immunotherapy really needs to be evaluated by a dermatologist or oncology team, because the treatment for each type is different.

Rare but Serious Skin Reactions

Most chemotherapy skin reactions are uncomfortable but manageable. A small number, though, cross into medical emergencies. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are severe reactions in which large areas of skin blister and peel away, leaving raw, exposed tissue. These have been reported with various chemotherapy regimens and carry a high mortality rate.⁶ The visual cue is unmistakable: the skin looks like it has been scalded, with large sheets lifting off and painful erosions on the mouth and eyes.

If you notice rapidly spreading blisters, skin that peels with minimal pressure, or involvement of the mucous membranes (inside the mouth, eyes, or genitals) during chemotherapy, treat it as an emergency. SJS and TEN are rare, but they require immediate medical attention and usually hospitalization. This is one reason oncology teams ask you to report any new skin change promptly, even if it seems minor at first.

Appearance Across Different Skin Tones

Most published photographs of chemo rash come from light-skinned patients, which creates a real gap for anyone with darker skin trying to identify what’s happening on their own body. The fundamental shapes are the same: papules, pustules, and flat patches. But on darker skin, the redness that defines these rashes in textbook photos may instead look dark brown, purple, or dusky rather than pink or red. The surrounding inflammation can be harder to see against melanin-rich skin, which sometimes leads to delayed recognition by both patients and clinicians.

Research has found that Black patients report skin problems during cancer treatment at higher rates than white patients. In one study, more than half of Black patients reported skin problems compared to about a quarter of white patients.⁷ The difference was not explained by the type of treatment received. This may reflect differences in skin biology, differences in detection and reporting, or both. Regardless of the cause, if you have darker skin and notice any change in texture, color, or sensation during treatment, it’s worth flagging to your care team even if the area doesn’t look classically “red.”

Post-inflammatory hyperpigmentation is another concern more common in darker skin. After the active rash resolves, the affected areas may leave behind dark marks that persist for weeks or months. These marks aren’t harmful, but they can be distressing, especially on the face.

Nail Changes That Accompany the Rash

Skin and nails are closely related tissues, and many of the drugs that cause rashes also damage the nail bed. Chemotherapy-associated paronychia, an inflammation of the skin folds around the nails, is particularly common with taxanes and EGFR inhibitors.⁸ The skin around the nail becomes swollen, red, and tender, sometimes oozing pus. The nail itself may become thickened, discolored, ridged, or brittle. In some cases, the nail partially lifts away from the nail bed.

These structural changes, combined with the immune suppression that comes with chemotherapy, make the nails vulnerable to secondary infections from bacteria, fungi, and yeast.⁹ If you notice increasing pain, spreading redness, or pus around a nail during treatment, it’s worth having it evaluated rather than assuming it’s just a standard chemo side effect. An untreated nail infection during immunosuppression can become a bigger problem quickly.

Why a Worse Rash Sometimes Means Better Treatment

One of the more counterintuitive findings in oncology is that patients who develop a more severe EGFR inhibitor rash tend to live longer. A meta-analysis of 24 trials in non-small-cell lung cancer found that skin rash was an independent predictor of both survival and slower disease progression. Patients who developed a moderate-to-severe rash were far more likely to respond to treatment than those with no rash.¹⁰ In two large trials of erlotinib, patients with a mild rash survived roughly two and a half times longer than patients with no rash, and those with a more severe rash survived even longer.¹¹

The connection has been explored as a potential surrogate marker for drug effectiveness, meaning the rash could signal that the drug is successfully blocking its target in the tumor as well as in the skin.¹² This doesn’t mean you should welcome a painful rash, and it doesn’t apply to all chemo drugs. But if you’re on an EGFR inhibitor and breaking out badly, it may offer some reassurance that the drug is doing its job. Your oncologist can put the rash severity in context alongside imaging and other markers.

Why the Rash Happens at a Biological Level

EGFR is a protein receptor found not just on tumor cells but also on normal skin cells, particularly the keratinocytes that make up the outer layer of your skin and line your hair follicles. When the drug blocks this receptor in the skin, it disrupts normal cell growth and turnover, leading to inflammation. Recent research suggests the mechanism goes beyond simple keratinocyte disruption: blocking EGFR in the skin may also unleash chemical signals called chemokines that draw immune cells into the skin, amplifying the inflammatory response.¹³ That’s why the eruption looks so angry and inflamed even though there’s no actual infection driving it.

For severe cases, roughly 8 to 12 percent of patients on EGFR inhibitors, the rash is bad enough that doctors consider reducing the drug dose.¹⁴ The dose-dependence of the rash is consistent with the biological story: more drug reaching EGFR receptors in the skin means more disruption and more inflammation.

How Doctors Grade the Severity

Oncology teams use standardized grading scales to describe how bad a skin reaction is. The most widely used is the Common Terminology Criteria for Adverse Events (CTCAE), which grades reactions from 1 to 5.¹⁵ For skin rashes, the grades break down roughly like this:

Grade 1: Bumps or redness covering a small area, with minimal or no symptoms. You might not even notice it without looking closely.
Grade 2: Bumps covering a larger area, with itching or tenderness that affects daily life but doesn’t prevent self-care.
Grade 3: Severe eruption covering a large body surface area, with significant pain, itching, or secondary infection. May limit your ability to care for yourself.
Grade 4: Life-threatening reactions like TEN or SJS, requiring hospitalization.

For EGFR inhibitor rashes specifically, a more detailed grading system has been proposed that also accounts for nail changes, dryness, itching, and the effect on quality of life, recognizing that the standard scale doesn’t always capture how burdensome these skin changes are for patients.¹⁶ When you hear your oncologist refer to your rash by grade, this is the framework they’re using.

Managing the Rash and Protecting Your Skin

There are two general strategies: treating the rash before it starts (prophylactic) or treating it once it appears (reactive). For EGFR inhibitor rashes, clinical data shows that both approaches produce similar survival outcomes. In one study, more than 90 percent of patients developed a rash regardless of strategy, and most oncologists ended up favoring reactive treatment.¹⁷ That said, many cancer centers still start oral antibiotics (like doxycycline or minocycline) at the beginning of EGFR inhibitor therapy, because even if they don’t prevent the rash entirely, they can reduce its severity.

For day-to-day skin care, international expert panels recommend a gentle, consistent routine. Mild, fragrance-free cleansers and thick moisturizers applied regularly can help manage the dryness that makes the rash worse.¹⁸ Research evaluating supportive skin care products during chemotherapy found that patients who used them consistently reported fewer and less bothersome skin reactions than those who used them sporadically.¹⁹ Sunscreen is particularly important because many chemotherapy drugs make the skin more sensitive to UV light, and sun exposure can worsen the rash and increase the risk of lasting discoloration.

Things to avoid: harsh soaps, alcohol-based toners, exfoliants, and hot water. Treat your skin as if it were sunburned, because the barrier function is compromised in much the same way. If over-the-counter moisturizers and gentle care aren’t controlling the symptoms, your oncology team can prescribe topical steroids, topical antibiotics, or adjust your treatment plan.

The Emotional Weight of Visible Skin Changes

Chemo rash sits in a difficult emotional space. Unlike hair loss, which most people expect with chemotherapy, skin changes can catch patients off guard. A rash concentrated on the face is visible to everyone you interact with, and it doesn’t have the cultural framing that hair loss does. Patients living with treatment-induced skin toxicities report that the changes erode their self-image and strain their relationships. For some, the skin changes become a reason to consider stopping treatment altogether.²⁰

The use of medical-grade camouflage cosmetics and non-pharmaceutical skin care products is increasingly recognized as part of supportive oncology care, not a vanity concern. Some cancer centers now have dedicated skin-care programs or refer patients to dermatologists who specialize in oncology-related skin issues. If skin changes during treatment are affecting how you feel about going out, interacting with others, or continuing therapy, raising it with your care team is not trivial. They’ve heard it before, and there are concrete things they can do to help.

When to Call Your Oncology Team About a Skin Change

Mild redness and a few bumps during chemotherapy are expected and usually manageable at home. But certain signs warrant a prompt call. Rapid spread over hours, blistering, skin peeling in sheets, involvement of the mouth or eyes, fever alongside a new rash, or signs of infection in an existing rash (increasing warmth, pus, red streaking, or worsening pain) all need urgent evaluation. The line between a routine drug rash and something dangerous can be thin, and oncology teams would rather get a call that turns out to be nothing than miss an early sign of SJS, TEN, or a secondary infection in an immunosuppressed patient. Keeping a photo diary of your skin on your phone, with consistent lighting and angles, gives your care team a visual timeline that can be far more useful than a verbal description during an office visit.